Requests for accelerated assessment are addressed to the European Medicines Agency (EMA) to request an accelerated review of a medicine’s marketing application, particularly indicated for medicines that may have a significant benefit to the public or fill an unmet need. They must be convincing and clearly highlight the importance and advantages over other existing therapies. With a strategic focus, we will strive to deliver well-structured documents with clear arguments that help authorities quickly assess the relevance to public health.